Dr. Steve Alley joined MBrace in February 2024 as the Chief Scientific Officer. Steve has over 20 years of experience at Seagen Inc, which was acquired by Pfizer in 2023.

Before joining MBrace, Steve was Executive Director, Scientific Integration and Strategy at Seagen Inc., where he led a cross-functional team in Translational Sciences. Steve was an integral part of Seagen, assuming various leadership roles in both research and development. Notably, Steve contributed to the development of the Seagen ADC technology platform and led the cross-functional team that discovered the Seagen Sugar Engineered Antibody technology platform.

Steve has contributed to 6 global oncology product registrations, published about 50 peer-reviewed manuscripts, and been granted 8 US patents covering innovative accomplishments in small molecule compositions of matter and uses as well as methods of making ADCs and enhanced antibodies. Prior to Seagen, Steve held a position in the Research Biology Department at Pathogenesis Inc., which was later purchased by Chiron Corp.

Steve received his B.A. in Chemistry from Linfield College in McMinnville, Oregon, a Ph.D. in Organic Chemistry from the University of Washington and completed a postdoctoral fellowship in Chemistry at The Pennsylvania State University.